Search explainers, questions, and medicine profiles.
The publication’s independent editorial identity. Research and editorial tools assist evidence review. No individual clinician or professional credential is claimed.
How we workSeparate semaglutide’s product-specific approvals from the weight-loss and cardiovascular trials that support particular uses.
Retatrutide now has peer-reviewed Phase 3 results, but strong trial findings and routine regulatory approval remain different milestones.
A cardiovascular headline becomes easier to assess when the event counts, baseline risk, and follow-up sit beside the relative effect.
Read the population, comparator, duration, analysis, and harms before deciding what a weight-loss headline really means.
Protein matters, but more is not a universal solution. Pair food planning with activity, function, and an individualized target.
The cagrilintide–semaglutide combination has Phase 3 evidence. Its analysis, study population, and regulatory status need separate labels.
A clear guide to appetite pathways, approved products, trial evidence, and the questions that matter before treatment.
A large randomized trial compared supported, quality-focused eating patterns—not every diet carrying a low-carb or low-fat label.
Orforglipron is now FDA-approved as Foundayo for adult weight management; oral delivery does not remove the need for safety review.
One weigh-in measures total body mass. A useful trend needs context, consistent conditions, and room for normal variation.
